Van Strum & Towne Inc. Has $1.85 Million Position in Pfizer Inc. (NYSE:PFE)

Van Strum & Towne Inc. increased its stake in Pfizer Inc. (NYSE:PFE) by 5.5% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 69,684 shares of the biopharmaceutical company’s stock after purchasing an additional 3,655 shares during the quarter. Van Strum & Towne Inc.’s holdings in Pfizer were worth $1,849,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. State Street Corp lifted its holdings in shares of Pfizer by 1.2% during the third quarter. State Street Corp now owns 290,460,600 shares of the biopharmaceutical company’s stock worth $8,405,930,000 after buying an additional 3,405,539 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Pfizer by 19.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company’s stock worth $4,124,330,000 after buying an additional 25,315,159 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Pfizer by 1.6% during the third quarter. Geode Capital Management LLC now owns 117,666,245 shares of the biopharmaceutical company’s stock worth $3,392,342,000 after buying an additional 1,855,419 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Pfizer by 22.4% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 38,068,879 shares of the biopharmaceutical company’s stock worth $1,101,713,000 after buying an additional 6,977,587 shares during the last quarter. Finally, Van ECK Associates Corp lifted its holdings in shares of Pfizer by 28.5% during the fourth quarter. Van ECK Associates Corp now owns 21,286,805 shares of the biopharmaceutical company’s stock worth $564,739,000 after buying an additional 4,726,549 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Trading Up 0.5 %

NYSE:PFE opened at $25.74 on Friday. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54. The business’s 50-day moving average price is $26.24 and its two-hundred day moving average price is $27.15. The firm has a market capitalization of $145.85 billion, a price-to-earnings ratio of 18.25, a PEG ratio of 0.64 and a beta of 0.61. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same period in the prior year, the company earned $0.10 earnings per share. The company’s revenue for the quarter was up 24.7% compared to the same quarter last year. On average, equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on PFE shares. Guggenheim restated a “buy” rating on shares of Pfizer in a research report on Wednesday. UBS Group lowered their price objective on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 8th. Truist Financial lowered their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. Citigroup lowered their price objective on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Finally, Bank of America restated a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, Pfizer presently has a consensus rating of “Moderate Buy” and an average target price of $31.92.

Insiders Place Their Bets

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the stock in a transaction on Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.06% of the company’s stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.